Eye Tracking for Concussions: When Marketing Claims Outpace the Science

Eye tracking technology for concussion detection is a promising frontier — but the gap between commercial marketing claims and independent scientific validation is a recurring and concerning pattern in this space.

The case that illustrates the gap

The case that illustrates this most clearly involves EYE-SYNC (now SyncThink), a VR goggle-based eye tracking device. The company reported 82% sensitivity for concussion detection based on company-sponsored research. However, independent post-market testing — the kind conducted by researchers without financial ties to the manufacturer — found sensitivity as low as 48%, according to analyses discussed in sports medicine conference proceedings and independent clinical reviews.

A 48% sensitivity means the device missed more than half of confirmed concussions. For a tool marketed as a concussion detection aid, that represents a fundamental performance gap.

A counter-example

Meanwhile, EyeBOX (Oculogica) has accumulated 16 peer-reviewed studies published in journals including the Journal of Neurotrauma and has received FDA clearance. Its evidence base, while not perfect, has been built through a combination of manufacturer-sponsored and independent research, providing a more reliable picture of real-world performance.

Questions to ask any technology provider

• Has this tool been validated by independent researchers?
• Are the studies published in peer-reviewed journals?
• What are the sensitivity and specificity values, and were they calculated using independent data?
• Is the device FDA-cleared, and if so, for what specific indication?

Our standard

At Headquarters, we only use assessment tools with robust, independently validated evidence bases. Our athletes deserve proven science, not marketing promises. We evaluate new technologies rigorously before incorporating them into our protocols. For the broader landscape, see our 7-technology overview.

Frequently asked questions